Viatris IncChange company Symbol lookupSelect an option...VTRS Viatris IncAMPX Amprius Technologies IncTPC Tutor Perini CorpLTRN Lantern Pharma IncJGGC Jaguar Global Growth Corporation IWHG Westwood Holdings Group IncBNOX Bionomics LtdPSO Pearson PLCERNA Eterna Therapeutics IncINDP Indaptus Therapeutics IncGo
Change company Symbol lookup
Select an option...
VTRS Viatris Inc
AMPX Amprius Technologies Inc
TPC Tutor Perini Corp
LTRN Lantern Pharma Inc
JGGC Jaguar Global Growth Corporation I
WHG Westwood Holdings Group Inc
BNOX Bionomics Ltd
PSO Pearson PLC
ERNA Eterna Therapeutics Inc
INDP Indaptus Therapeutics Inc
Health Care : Pharmaceuticals | Mid Cap Value
Company profileViatris Inc. (Viatris) is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company’s ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands and complex generics. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 7, 2023 | $0.75 | Q2 Consensus of 7 analysts | $0.71 | Difference from consensus | 5.63% | Q3 Earnings will announce | (Unconfirmed) November 6, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
VTRS's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.